The search term is “best NAD⁺ supplement for women”, and it carries an assumption worth pulling apart before you spend anything: that somebody makes a version for women, and that it was compared against the other one.
Nobody has. But the women-only evidence that does exist is more interesting than the premise, and it is not what the pink-labeled bottles are selling.
The best-known positive trial in this field was done in women
In 2021, Science published a 10-week randomized, placebo-controlled, double-blind trial of nicotinamide mononucleotide in postmenopausal women with prediabetes who were overweight or obese. Insulin-stimulated glucose disposal — measured by hyperinsulinemic-euglycemic clamp, the reference method rather than a blood-sugar proxy — increased after NMN and did not change after placebo. Skeletal muscle insulin signaling increased too, along with expression of genes related to muscle remodeling [1].
That is a genuine, carefully measured result, and it is the single most cited positive finding in the NAD⁺ literature. It is also narrow in a way the marketing never mentions. It is about how muscle responds to insulin, in women who already had prediabetes. It is not a finding about energy, skin, hair, mood, sleep or aging, and it was never a finding about healthy women. If you want the wider picture, what the trials measured goes through the rest claim by claim.
The menopause study, reported properly
In 2026 a pilot study asked something closer to what women actually search for. Forty healthy women over 35 — 32 reporting symptoms of the menopause transition, 8 not — took a combination of nicotinamide riboside 250 mg and pterostilbene 50 mg daily for seven days, with a symptom survey and urine collection before and after (n = 40). In the symptomatic group, the frequency and magnitude of bloating, hot flashes and poor sleep all fell significantly against baseline, and the urinary estradiol-to-estrone ratio rose. The group without symptoms reported no significant change [2].
Now the caveats, all of which are in the paper and none of which survive the trip to a product page.
It was open-label: every participant knew she was taking the supplement. There was no placebo group — the comparison is each woman against her own baseline, which is the design most vulnerable to the expectation of feeling better. The outcome was a self-reported questionnaire. It ran for seven days. And the product was a combination of a NAD⁺ precursor with pterostilbene, so nothing in the result can be attributed to the NAD⁺ side of it.
That is not a reason to dismiss the study. Pilots are supposed to look like this, and the authors labeled theirs accurately. It is a reason not to let it be quoted as proof that NAD⁺ treats menopause symptoms, which is the use it will be put to.
What has not been studied in women at all
We ran three more searches on September 13, 2026. A search for NMN ovarian oocyte women clinical trial returned zero results. A search for nicotinamide riboside hot flashes randomized placebo women returned zero results. A search for nicotinamide mononucleotide skin women randomized trial returned zero results. A fourth, for nicotinamide mononucleotide postmenopausal women, returned three records of which exactly one is a human trial — the 2021 clamp study above. The other two are mouse models.
Fertility and egg quality are the loudest NAD⁺ claims aimed at women in their thirties, and they rest entirely on rodent work. Skin is the second loudest, and the one laboratory study we could find of a topical-style NAD⁺ preparation was done in cultured cells and skin explants, not on anyone.
Is a “women’s formula” different?
Not in any way that has been tested. The trials above used plain nicotinamide mononucleotide and plain nicotinamide riboside — the same two molecules sold to everybody, and they differ from each other more than either differs by who takes it. No trial has compared a women’s-marketed NAD⁺ product against a standard one, and no dose has been established as sex-specific.
The dose-ranging work that does exist enrolled both sexes and found the same thing in all of them. A randomized, multicenter, double-blind trial of 80 healthy middle-aged adults (n = 80) gave placebo or 300, 600 or 900 mg of NMN daily for 60 days; blood NAD⁺ rose significantly in every NMN group at day 30 and day 60, against both placebo and baseline (all p ≤ 0.001) [3]. A separate safety study of 1,250 mg daily for four weeks was run in 31 healthy adult men and women together, and reported no severe adverse events[4].
So when a label says “formulated for women”, it is describing the marketing, not a difference anyone has measured in the NAD⁺ component.
The one measured biological difference
It is not about supplements. A study of pelvic skin samples from 49 people aged newborn to 77 found NAD⁺ declining with age in both sexes, but the pattern around it differed. In men, PARP activity rose steeply with age (p < 0.0001) and SIRT1 activity fell (p = 0.007); the authors describe both associations as “less evident in females”. The NAD⁺ decline itself was shallower in women: p = 0.01, r = −0.537, against p = 0.001, r = −0.706 in men [5].
Read that as a description of aging, not a prescription. It tells you the curves are not identical. It does not tell you that either sex benefits more from pushing levels back up, because that comparison has never been run.
What we would actually tell a friend
Buy on the molecule and the price, not the pronoun. The evidence in women is one strong narrow trial in prediabetes and one open-label seven-day pilot, both using ordinary oral precursors — the cheapest format on the shelf, and the only one with randomized human data behind it at all. The precursor with the largest published research base is Tru Niagen, which we earn nothing from.
And if a product is charging a premium for being a women’s version, that premium is buying label design. Our price table shows what the same milligrams cost without it.